FI
PTGX icon

Fosun International’s Protagonist Therapeutics PTGX Stock Holding History

Fosun International’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-47,513
Closed -$569K – 279
2019
Q2 		$569K Hold
47,513
– – 0.04% 212
2019
Q1 		$585K Sell
47,513
-49,000
-51% -$433K 0.04% 210
2018
Q4 		$609K Buy
+96,513
New +$766K 0.04% 195

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fosun International's PTGX Position: Q3 2019 in Review

Fosun International sold out of Protagonist Therapeutics (PTGX) in Q3 2019, closing a stake of 47,513 shares — an estimated $569K sold.

Fosun International first reported a position in PTGX in Q4 2018 and held it in 3 quarters. The position peaked at $609K in Q4 2018. 76 funds tracked by Wall St. Rank hold PTGX as of Q3 2019.

  • Fosun International reported no remaining Protagonist Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Fosun International sold 47,513 Protagonist Therapeutics shares in Q3 2019, an estimated $569K.
  • Fosun International first reported a position in Protagonist Therapeutics in Q4 2018 and held it in 3 quarters.
  • Fosun International's Protagonist Therapeutics position peaked at $609K in Q4 2018.
  • 76 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2019.

Based on Fosun International's 13F filing for Q3 2019, filed 12 Nov 2019.